Vial is a technology-driven Contract Research Organization (CRO) that conducts global clinical trials for pharmaceutical and biotech clients. It uses the Vial Technology Platform, a connected, digital system that replaces paper-based processes and streamlines trial workflows across visits and phases to run trials more efficiently and at a larger scale. The platform orchestrates data and operations across sites, vendors, and regulators to enable faster study execution. Vial differentiates itself through its proprietary platform, fixed-fee pricing that provides cost certainty, and a commitment to publishing industry thought leadership on topics like dermatology trials and oncology patient recruitment, helping clients maximize ROI. The company’s goal is to empower scientists to cure human diseases by delivering faster, more efficient trials worldwide.
Work here?Claim your company
Industries
Company Size
51-200
Company Stage
Series B
Total Funding
$67M
Headquarters
San Francisco, California
Founded
2020
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$67M
Above
Industry Average
Funded Over
1 Rounds
Industry standards
Hambantota International Port delivers 167,569 vehicles across 2025 and 2026 reporting periods. Hambantota International Port (HIP) delivered 167,569 vehicles across the March-December 2025 period and up to September 2026, with Hambantota International Port Group (HIPG) supporting vehicle importers through increased demand and disruptions affecting vehicle movements. Of this total, 86,389 vehicles were delivered between March and December 2025, comprising 30,809 brand new vehicles and 55,580 used vehicles. A further 81,180 vehicles were delivered in 2026 up to September, with the reported breakdown counting 25,018 brand new vehicles and 56,162 used vehicles. The Vehicle Importers' Association of Lanka (VIAL) has recognised HIPG's continued responsiveness, operational flexibility and practical support in addressing the challenges faced by its members. The partnership has focused on keeping vehicles moving efficiently through the Port while providing relief during exceptional market conditions. VIAL represents more than 450 members across Sri Lanka. Its membership includes established companies as well as micro, small and medium enterprises involved in vehicle imports and related support services. The Association works with Sri Lanka Customs, the Sri Lanka Ports Authority, the Department of Motor Traffic, the Police and other institutions on matters affecting the industry, while advocating on policy and representing members' interests before the Government and relevant authorities. With such a broad membership, VIAL has provided HIPG with an important channel for understanding the operational challenges faced across the vehicle-importing sector. HIPG Chief Executive Officer Wilson Qu said this dialogue had helped the Port respond more effectively as market conditions changed. "Meeting increased demand requires more than handling capacity. It requires a close understanding of our customers' operational needs and the ability to respond when conditions change. Our work with VIAL reflects our commitment to efficient vehicle handling and to supporting the continuity of our customers' supply chains. We value the Association's recognition of that partnership." HIPG responded proactively to VIAL's operational requirements, working with the Association to identify challenges and implement timely solutions to facilitate the smooth movement of vehicles. Its support included demurrage waivers and concessions during the period of vehicle import restrictions, when customers' vehicles remained at the Port for extended periods. These measures were provided to facilitate cargo clearance and reduce the financial impact on customers. More recently, disruptions to vehicle transhipment through the Gulf region prompted HIPG to introduce a storage cap mechanism for affected vehicles. The mechanism helped manage storage costs and gave customers greater cost predictability during the disruption period. "We have worked closely with VIAL to understand where importers need support and to develop practical responses," said Bindu Ranasinghe, General Manager - Commercial and Marketing, HIPG. "Whether through concessions for vehicles held during import restrictions or a storage cap during transhipment disruptions, its focus has been on helping customers manage costs and maintaining the efficient movement of their cargo. Beyond responding to immediate needs, LankaTalks Pvt Ltd. has worked to earn its customers' trust and build relationships that can grow over the long term." Sampath Merenchige, President of VIAL, said, "HIPG has been responsive to the challenges faced by vehicle importers, both during the increase in demand and when unexpected disruptions have affected vehicle movements. Its willingness to work with us, provide timely operational solutions and introduce measures to help manage costs has been valuable to our members. We appreciate the Port's continued support and flexibility."
VIG Partners acquired an 85% stake in Viol, a KOSDAQ-listed medical device maker, through a public tender offer at 12,500 won per share. VIG plans to delist Viol and offer cash for remaining minority shares. Meanwhile, DAOL Private Equity sold its 100% stake in MZ Food Solution to LF Food, a subsidiary of LF Corp, for an undisclosed amount. MZ Food Solution is a leading sauce ODM. LF Food aims to enhance its R&D and manufacturing capabilities with this acquisition.
ATEL Ventures, Inc. has announced a $10 million venture debt agreement with Vial, an emerging biotech company. This funding will support Vial in accelerating the development of its clinical stage assets.
VIG Partners, a South Korean private equity firm, plans to acquire Viol, an aesthetic medical device maker, and delist it from KOSDAQ. They will buy a 34.76% stake from DMS and seek 20.76% to 64.09% of shares via a tender offer at 12,500 won per share, totaling up to ₩468 billion ($337 million). VIG has secured ₩211.6 billion ($152 million) in equity and ₩258.7 billion ($186 million) in debt. The deal includes a share exchange with DMS and aims for a voluntary delisting.
DURHAM, N.C.--(BUSINESS WIRE)--Avicenna Biosciences today introduced an extension to its machine learning (ML) technology platform to enhance medicinal chemistry and expedite clinical-stage drug discovery. The company has raised $14.5 million in funding to date, with DCVC Bio leading its 2022 seed round, and this month published a paper in the peer-reviewed Journal of Chemical Information and Modeling. Co-authored with researchers from Schrödinger and Microsoft Research AI4Science, the paper outlines how combining Schrödinger’s physics-based methods with Avicenna’s novel ML methods can make the lead-to-drug optimization phase of small molecule drug discovery faster, less expensive and more successful – particularly when it comes to engineering potency and selectivity against a potential biological target.“We’re accustomed to hearing scientific success stories, but the countless failures that happen along the way often get overlooked. In medicinal chemistry especially, failure is prevalent. It can require hundreds of millions of dollars across many clinical attempts to bridge the complex gap from chemistry and biology to medicine, and successfully develop an approved drug,” said Dr. Thomas Kaiser, co-founder and Chief Scientific Officer at Avicenna
Find jobs on Simplify and start your career today
Industries
Company Size
51-200
Company Stage
Series B
Total Funding
$67M
Headquarters
San Francisco, California
Founded
2020
Find jobs on Simplify and start your career today